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CEQUEL the sequel: bipolar disorder combination therapy
Hollywood sequels are usually safe, predictable follow-
ups to blockbuster movies that somehow hit upon 
a magic winning formula. Understandably, movie 
studios and ﬁ lm producers try to replicate their success 
by simply extending the story and using the same 
actors. This strategy seldom meets expectations—
making the exceptions all the more remarkable—eg, 
the sequels to Star Wars, The Godfather, and (perhaps 
more controversially) Back to the Future.  
Published in 2010, the BALANCE study1 was 
psychiatry’s Oscar equivalent of The King’s Speech (Best 
Motion Picture, 2010). Like its cinematic counterpart, 
it retold a story about an element that we know, and 
always have known, is “King”, but that, because of a 
faltering voice (in lithium’s case, its so-called orphan 
drug status), has been forced to work in silence.2 The 
ﬁ ndings of the BALANCE study revitalised clinical 
interest in lithium and repositioned this essential 
element at the heart of bipolar disorder maintenance 
therapy.1 Scientiﬁ cally, the landmark study tested 
combination therapy—a strategy that is in eﬀ ect the 
norm in psychiatric practice, and yet for which few 
randomised controlled trials are done. BALANCE 
also studied the least investigated treatment phase 
of the illness—namely, prophylaxis. Though widely 
acknowledged as critical to functioning and overall 
wellbeing, prophylaxis is often considered too diﬃ  cult 
to investigate—partly because of the length of time it 
takes to observe meaningful outcomes. But at least 
lithium has speciﬁ city of action in this phase of the 
illness, and is arguably most eﬀ ective as maintenance 
therapy.3
In comparison with mania, bipolar depression is 
less well characterised and therefore its management 
is much less precise. For instance, it is mania, not the 
depressive phase of bipolar disorder, that deﬁ nes the 
illness, and phenomenologically bipolar depression 
is indistinguishable from major depression. Hence, 
all the treatments for bipolar depression have been 
adopted, with not a single drug developed speciﬁ cally 
for it. For example, antidepressants target major 
depression, antipsychotics treat schizophrenia, and 
anticonvulsants control epilepsy. Consequently, the 
eﬀ ective treatment of depression in bipolar disorder 
remains unsatisfactory and problematic, especially 
because antidepressants are generally thought to 
be less eﬀ ective in its treatment than they are for 
major depression and they might instead precipitate 
a treatment emergent aﬀ ective switch or induce a 
mixed state.4 Thus, most clinical practice guidelines 
advise using antidepressants sparingly, and avoiding 
monotherapy when possible, especially in bipolar 
1 disorder.5 Instead, conventional antidepressants 
should be prescribed alongside an antimanic agent 
(for example lithium), an antipsychotic, or an 
anticonvulsant. The drugs with the best evidence in 
this regard are quetiapine, lurasidone, olanzapine, 
lithium, valproate, and lamotrigine. All of these drugs 
can be given as monotherapy and therefore a study 
combining quetiapine and lamotrigine, possibly the 
two most common options from this menu for the 
treatment of bipolar depression, is both relevant and 
important.6 
As a sequel to BALANCE, the combination therapy 
study CEQUEL published in The Lancet Psychiatry does 
not disappoint.7 But to facilitate success, John Geddes 
and colleagues have drawn on many of the original 
“cast” and produced the study against a backdrop of 
real-world practice. Here, quetiapine is often given 
short-term to ameliorate acute symptoms, especially 
those associated with anxiety, and this allows other 
coprescribed drugs to gain traction. For example, 
when used in conjunction with quetiapine in this Ktsd
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manner, lamotrigine, which is known to be more 
eﬀ ective longer term than acutely, is able to achieve a 
therapeutic level and exert its actions under the initial 
cover of the antipsychotic, which can then be gradually 
tapered and withdrawn. 
In CEQUEL, the investigators skillfully take advantage 
of the synergy between quetiapine and lamotrigine 
that arises from their diﬀ ering, but complementary, 
mechanisms of action and the separate timescales over 
which they exert their eﬀ ects. The study tests both the 
short-term and long-term beneﬁ ts of combination 
therapy, and shows that lamotrigine add-on therapy 
to quetiapine is eﬀ ective at 3 months (mean diﬀ erence 
in QIDS-SR16 total score between the group receiving 
lamotrigine versus the placebo group at 12 weeks was 
–1·73 [95% CI –3·57 to 0·11]; p=0·066) and that the 
improvement is sustained for at least a year (–2·69 
[–4·89 to –0·49]; p=0·017). This is the primary aim 
of CEQUEL, but most intriguing is exploration of the 
additional eﬀ ect of folic acid, which the investigators 
cleverly include in the factorial study design. 
The precise role of folic acid in depression,8 and 
more speciﬁ cally its role in bipolar depression, 
requires further investigation. Its involvement in 
methylation pathways in the one-carbon cycle, in 
particular the synthesis of S-adenosyl methionine 
from homocysteine, suggests that it facilitates 
antidepressant actions of medications thought to 
act via monoamine neurotransmitter systems.9 In 
CEQUEL, lamotrigine and folic acid interact such that 
the latter diminishes the additive eﬀ ects of lamotrigine 
on quetiapine at 12 weeks. The authors speculate that 
this is a pharmacokinetic or pharmacodynamic eﬀ ect—
the latter being mediated via a common enzyme or 
receptor site. The precise nature of the interaction 
is unknown, but it highlights the potential role of 
neutraceuticals in the treatment of mood disorders, 
and the need for psychiatrists to additionally consider 
the nutritional and metabolic health of their patients. 
The eﬀ ects of medication withdrawal, diagnostic 
heterogeneity, and small sample size often confound 
ﬁ ndings from bipolar disorder trials. These are all 
relevant concerns for CEQUEL, which is additionally 
constrained by reliance on self-report measures for 
assessing key outcomes. However, the latter is also a 
potential strength and perhaps an advance, for two 
reasons. First, a patient rating their own symptoms 
reﬂ ects real-world practice, where clinicians are 
dependent upon what patients report. Second, with 
the advent of mobile technologies that can more 
closely and accurately monitor and capture both 
emotions and activity, self-report is likely to become 
increasingly integral to future clinical trials. 
The ﬁ ndings from CEQUEL, although interesting 
and clinically relevant, still need replication and 
corroboration from both randomised controlled trials 
and empirical research. Therefore let’s hope there are 
more sequels to come, and that CEQUEL is simply the 
ﬁ rst of many such studies that aim to improve the 
treatment of bipolar depression.  
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